Generic Version of Hepatitis C Treatment can Improve Life Expectancy
A new study reports that generic varieties of drug antivirals for treatment of Hepatitis C infections are cost-effective and can improve life expectancy with less complications.
Study was carried out by researcher Dr Rakesh Aggarwal from the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. Results of the study show that the generic versions of drugs such as Sofosbuvir, Ledipasvir, and Daclatasvir are cost-effective for Indian patients. Lifetime healthcare costs was observed to be reduced by around Rs 84, 000 per person while the life expectancy increased by eight years as compared to those who did not receiving any treatment. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe
The treatment with generic drugs became cost-effective within two years and cost-saving within 10 years of starting treatment. Cost saving was sooner for patients with the advanced disease across all age groups irrespective of the gender. The findings of the study encourage people suffering from Hepatitis C to opt for generic medicines to prevent complications and motivate doctors and policy makers to focus on the treatment of patients with advanced disease.
A total of 11 million people in India are suffering from chronic Hepatitis C infection, which is a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and other liver-related disorders. Hepatitis C infection have major economic implications due to expenditure on testing, treatment, and number of working hours.
According to Generic Drugs Market report Published by Coherent Market Insights, generic drugs yield the same therapeutic effect and are prescribed in the same dosing, with the same quality, and same the way of consumption and usage. Major advantage of generic drug is that they are cost-effective and affordable. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe
You may be interested
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market to Witness Robust Expansion Throughout the Forecast Period 2017 – 2025Albert R - October 22, 2018
CMI released a new market study on 2017-2025 Lysosomal Acid Lipase (LAL) Deficiency Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through…
Anxiety Disorders and Depression Treatments Anxiety Disorders and Depression Treatments Market is forecasted to witness a thriving growth by 2025Albert R - October 22, 2018
CMI released a new market study on 2017-2025 Anxiety Disorders and Depression Treatments Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages…
Surgical Sutures Market 2018: Record Overwhelming Hike in Revenues by 2026Albert R - October 22, 2018
CMI released a new market study on 2017-2025 Surgical Sutures Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to…